Omniose

About:

Omniose is an early stage biotechnological company.

Twitter/X: Omniose

Top Investors: National Institute of Allergy and Infectious Diseases, National Institutes of Health, Arch Grants, BioGenerator

Description:

Omniose is an early stage biotechnological company developing next-generation conjugate vaccines against infectious diseases using our proprietary in vivo conjugating technology.

Total Funding Amount:

$9.65M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

St Louis, Missouri, United States

Founded Date:

2016-01-01

Contact Email:

info(AT)vaxnewmo.com

Founders:

Christian Harding, Christine Szymanski, Mario Feldman

Number of Employees:

1-10

Last Funding Date:

2023-09-27

IPO Status:

Private

Industries: